Amendment #3 to Project Rider #1, effective as of December 16, 2020, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017
Exhibit 10.10.5
AMENDMENT #3
TO
PROJECT RIDER #1
COLLABORATION AGREEMENT
This Amendment #3 to Project Rider #1 (Amendment #3) is entered into effective as of the date of the final signature executing this Amendment #3 (Amendment #3 Effective Date) by and between Magenta Therapeutics, Inc. (Magenta) and National Marrow Donor Program d/b/a Be The Match Biotherapies (BTMB) (each a Party and collectively the Parties).
WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017 and a Project Rider, effective December 6, 2017 (as amended by that certain Amendment #1, effective December 6, 2018 and Amendment #2, effective November 13, 2019, Project Rider #1); and
WHEREAS, the Parties agree to extend the Term and Payment Schedule of the Project Rider #1.
NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB agree to the following amendment as follows:
Amendment to Project Rider #1
1. | Delete the Payment Schedule in Section D. Compensation of BTMB of Project Rider #1 in its entirety and replace it with the following to read as follows: |
PAYMENT SCHEDULE
For Services provided by BTMB during Calendar Year 2021 (January 1, 2021 through December 31, 2021), Magenta will pay BTMB a fixed price quarterly payment of $17,500. | BTMB will invoice $17,500 every January 15th for consulting services occurring during the period commencing January 1st and ending March 31st.
BTMB will invoice $17,500 every April 15th for consulting services commencing April 1st and ending June 30th.
BTMB will invoice $17,500 every July 15th for consulting services commencing July 1st and ending September 30th.
BTMB will invoice $17,500 every October 15th for consulting services commencing October 1st and ending December 31st. |
2. | Delete Section E. TERM. of Project Rider #1 in its entirety and replace it with the following to read as follows: |
E. TERM. The term of this Rider shall commence on the Rider effective date set forth above and continue and remain in effect through December 31, 2021.
[Remainder of page intentionally left blank.]
2
This Amendment #3 is executed by individuals who are duly authorized to legally bind their respective parties as of the Amendment #3 Effective Date:
MAGENTA THERAPEUTICS, INC. | NATIONAL MARROW DONOR PROGRAM d/b/a BE THE MATCH BIOTHERAPIES | |||||||
By: | /s/ Christina Isacson | By: | /s/ Mary Frey | |||||
Authorized signature | Authorized signature | |||||||
Christina Isacson | Mary Frey | |||||||
(Typed/Printed Name) | (Typed/Printed Name) | |||||||
Title: | Chief Business Officer | Title: | Contracts & Procurement Director | |||||
Date: | 12/16/20 | Date: | 12/7/2020 |
3